Is multiple myeloma hereditary?
Reading File
Searching PubMed
"multiple myeloma" AND hereditary AND genetics
Searching the Web
multiple myeloma hereditary familial risk genetic predisposition 2024
Finding Sources
Reading Article
PMID: 39721861
Reading File
I now have solid information from the textbook and current literature. Here is a thorough answer:
Is Multiple Myeloma Hereditary?
Short answer: partially, but not strongly. Multiple myeloma is not a classic hereditary cancer with a single high-penetrance gene (like BRCA1/2 in breast cancer), but there is a clear familial and genetic component.
Familial Risk
- Multiple myeloma has been reported in familial clusters of two or more first-degree relatives and in identical twins (Goldman-Cecil Medicine, p. 1977).
- First-degree relatives of someone with multiple myeloma have approximately 2-4x the population risk of developing the disease.
- This elevated risk also extends to the myeloma precursor, monoclonal gammopathy of undetermined significance (MGUS), which precedes virtually all myeloma cases and progresses to myeloma at roughly 1% per year.
What Drives the Hereditary Risk?
The inherited contribution comes from several layers:
1. Germline (inherited) rare variants - high penetrance:
A small number of families carry rare pathogenic germline mutations. Genes implicated include:
- DIS3 (exome sequencing studies)
- KDM1A / LSD1 (lysine-specific demethylase)
- CDKN2A
- No single dominant gene accounts for most familial cases.
2. Common genetic variants - low penetrance (GWAS findings):
Genome-wide association studies (GWAS) have identified multiple single nucleotide polymorphisms (SNPs) at loci such as 3p22.1, 7p15.3, 3q26.2, 6p21.33, 17p11.2, 22q13.1, and others. Each variant individually confers only a modest increase in risk, but in combination they contribute meaningfully to population-level susceptibility.
3. Somatic (acquired) mutations - not heritable:
The chromosomal changes seen within the cancer cells themselves - translocations involving the IgH locus (14q32), RAS mutations (KRAS, NRAS in ~20-25% of cases), MYC abnormalities, and deletions of 17p, 1p - are acquired, not inherited. These drive progression from MGUS to active myeloma.
MGUS as the Hereditary Intermediate
Almost all myeloma cases evolve from a precursor MGUS phase. The progression model follows a "two-hit" genetic model - about 1% of MGUS cases per year become overt myeloma. Families with a history of myeloma often show familial clustering of MGUS as well, suggesting a shared inherited predisposition at the precursor stage.
Environmental Factors Also Play a Role
The cause of multiple myeloma is not purely genetic. Radiation, benzene, organic solvents, herbicides, and insecticides have all been implicated. Occupational exposure to agricultural chemicals and petroleum products appears more common in familial clusters, suggesting gene-environment interactions.
Clinical Implications
A 2025 review in Seminars in Hematology (Bodnar et al., PMID 39721861) advocates for routine germline screening in high-risk patients - specifically those with:
- A strong family history of myeloma or other cancers
- Early-onset disease (diagnosed before age 50)
- Personal history of multiple cancers
Summary Table
| Feature | Status |
|---|---|
| Strongly hereditary (single gene) | No |
| Familial clustering | Yes |
| Relative risk in 1st-degree relatives | ~2-4x |
| Known germline genes | DIS3, KDM1A, CDKN2A (rare) |
| GWAS risk loci identified | Yes (20+ loci) |
| Precursor (MGUS) also heritable | Yes |
| Environmental factors contribute | Yes |
The bottom line: if you have a first-degree relative with multiple myeloma, your risk is modestly elevated. Genetic counseling and periodic screening (especially if MGUS is detected) may be appropriate, but most myeloma cases arise without any family history.
Does it have a cure
Finding Sources
Searching PubMed
"multiple myeloma" AND (cure OR "long-term remission" OR "CAR-T")
Searching the Web
multiple myeloma cure 2024 2025 treatment outcomes CAR-T stem cell
Reading File
Reading Article
PMID: 38943315
Reading File
Reading File
Reading File
Reading File
I now have comprehensive information. Here is a thorough answer:
Does Multiple Myeloma Have a Cure?
The honest answer: not reliably, no. Multiple myeloma is generally considered a treatable but not curable disease for the vast majority of patients. However, the picture is more nuanced than a flat "no."
What the Evidence Says
Goldman-Cecil Medicine states explicitly:
"Autologous transplantation is not curative, but it prolongs event-free and overall survival."
Despite this, a meaningful proportion of patients achieve deep, prolonged remissions - and some long-term remissions may effectively be functional cures, especially in younger, standard-risk patients.
Current Treatment Approach
Treatment is staged and increasingly personalized. Per the 2024 update by Rajkumar in Am J Hematol:
1. Transplant-eligible patients (~50% of newly diagnosed)
- Induction: Bortezomib + Lenalidomide + Dexamethasone (VRd), often with the addition of Daratumumab (anti-CD38 antibody) in high-risk cases
- Followed by autologous stem cell transplant (ASCT) with high-dose melphalan conditioning
- Then maintenance therapy (lenalidomide for standard risk; bortezomib + lenalidomide for high risk)
- Early transplant mortality is very low (<1%)
2. Transplant-ineligible / frail patients
- VRd or Daratumumab + Lenalidomide + Dexamethasone (DRd) for 8-12 cycles, then maintenance until progression
- No curative intent
3. Relapsed/refractory disease
- Triplet regimens with agents from different drug classes (proteasome inhibitors, IMiDs, monoclonal antibodies)
- CAR-T cell therapies: Idecabtagene vicleucel (ide-cel) and Ciltacabtagene autoleucel (cilta-cel) - both targeting BCMA (B-cell maturation antigen), which is almost universally expressed on myeloma cells
- Bispecific antibodies: Teclistamab, elranatamab, talquetamab (investigational/approved)
- These newer approaches are showing impressive response rates in heavily pre-treated patients
The Role of CAR-T Therapy - Closest to a "Cure"?
CAR-T cell therapies represent the most exciting recent development. Cilta-cel in particular has shown:
- Response rates >95% in some relapsed/refractory populations
- Deep, sustained remissions in a subset of patients
- However, a 2024 meta-analysis in Nature Medicine (PMID 38977912) notes that non-relapse mortality after CAR-T is not trivial and must be weighed against benefit
Whether CAR-T translates to true long-term cures at the population level is still being established, as follow-up data matures.
Survival Outlook
The median survival has improved dramatically over the past two decades:
| Era | Median survival |
|---|---|
| Pre-novel agents (~2000) | ~3 years |
| With IMiDs/proteasome inhibitors | ~5-7 years |
| With current quadruplet regimens + ASCT | 10+ years for standard risk |
| High-risk myeloma | Still ~3-5 years |
Some younger, standard-risk patients treated with modern regimens and ASCT are now living 15-20 years, blurring the line between "remission" and "cure."
Why It Keeps Relapsing
The fundamental challenge is that myeloma cells in the bone marrow develop resistance over time. Even after achieving minimal residual disease (MRD)-negative status (no detectable cancer cells by highly sensitive testing), tiny reservoirs of genetically diverse myeloma cells survive and eventually re-emerge. This is why maintenance therapy is given after transplant.
Bottom Line
- Standard-risk myeloma in a younger patient with modern therapy: very long remissions are common, and the concept of "functional cure" is being seriously discussed in the field
- High-risk myeloma (del17p, t(4;14), gain 1q, "double-hit" or "triple-hit"): outcomes remain poor and relapse is nearly universal
- CAR-T and bispecific antibodies are genuinely changing the landscape for relapsed disease and may eventually move earlier in the treatment sequence
- No treatment is currently considered definitively curative across the board
Can multiple myeloma be transferred from father to son
Finding Sources
Searching the Web
can multiple myeloma be passed from parent to child inherited risk transmission
Here is a clear, direct answer:
Can Multiple Myeloma Be "Transferred" From Father to Son?
No - the cancer itself cannot be transferred. Multiple myeloma is not contagious and cannot pass from one person to another through contact, blood, touch, or any other means. The cancer cells in a father's body cannot enter and grow in his son's body.
However, there are two distinct concepts worth understanding:
1. The Cancer Itself - NOT Transferable
The malignant plasma cells in myeloma are the father's own cells that have acquired mutations over his lifetime. These are called somatic mutations - they happen inside the body after birth and are not present in sperm or eggs. They die with the patient and cannot be passed to children.
2. Genetic Risk - CAN Be Inherited (Partially)
What CAN be passed from father to son is a slightly elevated genetic susceptibility - a predisposition that makes myeloma somewhat more likely to develop, not a guarantee that it will.
This works in two ways:
a) Rare high-penetrance germline variants:
Recent research from Roswell Park Cancer Center (published in Blood Cancer Discovery) found that pathogenic variants in BRCA1, BRCA2, and other DNA repair genes are more common in myeloma patients than in healthy controls - and patients with these variants tend to be diagnosed younger and have a family history of cancer. These germline variants CAN be passed from father to son.
b) Common low-risk genetic variants (GWAS loci):
Multiple common SNPs across 20+ chromosomal locations modestly increase myeloma risk and can be inherited. No single one causes myeloma, but combinations contribute to susceptibility.
What This Means in Practice
| Question | Answer |
|---|---|
| Can dad's cancer cells infect his son? | No - impossible |
| Does the son have higher risk than the general population? | Yes - roughly 2-4x higher |
| Is the son guaranteed to get myeloma? | No - most sons of myeloma patients never get it |
| Should the son be screened? | Yes - periodic monitoring may be reasonable, especially if he develops any symptoms |
What the Son Can Watch For
The precursor condition MGUS (monoclonal gammopathy of undetermined significance) often comes before myeloma and can be detected by a simple blood protein test. Sons of myeloma patients have an elevated risk for MGUS too. Periodic blood tests (serum protein electrophoresis, free light chains) in adulthood can detect this early.
Symptoms that should prompt a doctor visit:
- Persistent bone pain (especially back or ribs)
- Unexplained fatigue or anemia
- Recurrent infections
- Kidney problems without clear cause
- Elevated calcium levels found incidentally
The bottom line: the father's myeloma cannot be "caught" or transferred, but the son carries a modestly elevated lifetime risk and would benefit from awareness and periodic screening in middle age onward.
How to explain it to a patient
Here is a patient-friendly explanation you can use or adapt in a clinical conversation:
Explaining Multiple Myeloma to a Patient
What is it?
"Your blood is made up of many different cells. One type, called plasma cells, lives in your bone marrow - the soft inside part of your bones. Their normal job is to make antibodies that fight infections.
In multiple myeloma, some of these plasma cells go rogue. They start growing out of control and making a useless, abnormal protein instead of helpful antibodies. Over time, these abnormal cells crowd out the healthy ones and cause problems throughout your body."
Why does it cause problems?
"Because these abnormal cells pile up in the bone marrow, they cause several issues:
- Weak bones - they eat away at bone tissue, causing pain and fractures
- Anaemia - fewer red blood cells means tiredness and breathlessness
- Infections - your immune system can't work properly
- Kidney problems - the abnormal protein clogs the kidneys
- High calcium - from damaged bones, causing nausea, confusion, and thirst"*
Is it contagious?
"Absolutely not. You cannot catch it from someone, and you cannot give it to anyone. It is not like a virus or infection."
Did I pass it to my children?
"The cancer itself - no. Your children cannot 'catch' your myeloma. However, some families do seem to have a slightly higher chance of developing it. Think of it like heart disease - having a parent with heart disease doesn't mean you will definitely get it, but it does mean it is worth keeping an eye on. Your children's risk is a little higher than average, but most people with a family history never develop it. We can talk about whether any simple blood monitoring makes sense for them."
Can it be cured?
"For most people, we cannot cure it completely - but we can control it very effectively, often for many years. Think of it like diabetes or high blood pressure: we may not be able to make it disappear forever, but with the right treatment we can keep it under control and help you live well.
For some patients - especially younger, healthier ones - treatments like a stem cell transplant can put the disease into a very deep sleep for a long time. Some of those patients may effectively be cured, though we are careful about using that word.
Treatments have improved enormously in the last 10-15 years. People are living much longer with myeloma today than they did before."
What does treatment involve?
"Treatment usually involves a combination of medicines - tablets and drips - that target the abnormal plasma cells. If you are fit enough, you may also be offered a stem cell transplant, which uses your own stem cells to help rebuild your bone marrow after high-dose treatment.
We will tailor everything to you - your age, your overall health, and how your myeloma is behaving."
What should I watch for?
"Tell us straight away if you notice:
- New or worsening bone pain
- Unusual tiredness
- Frequent infections or fevers
- Swelling or reduced urination
- Feeling confused or very thirsty"*
Tips for the conversation
| Do | Avoid |
|---|---|
| Use simple analogies ("cells gone rogue", "bone marrow factory") | Medical jargon like "paraprotein", "CRAB criteria", "cytogenetics" unless the patient asks |
| Acknowledge fear and give space for questions | Rushing through information |
| Emphasise what CAN be done, not just the diagnosis | Leading with statistics like median survival |
| Write key points down or give a leaflet | Assuming they will remember everything |
| Invite a family member to be present |
A useful closing line:
"I know this is a lot to take in. You don't need to understand everything today. What matters right now is that we have a plan, I'm here to answer your questions, and you are not dealing with this alone."
Chemo for multiple myeloma
Finding Sources
Searching PubMed
"multiple myeloma" AND chemotherapy AND treatment
Searching the Web
multiple myeloma chemotherapy regimens 2024 2025 first line treatment guidelines
Reading File
Reading File
Reading File
Here is a comprehensive breakdown of chemotherapy and all systemic treatments for multiple myeloma:
Chemotherapy & Systemic Treatment of Multiple Myeloma
Modern myeloma treatment goes well beyond traditional chemotherapy. The field now uses five broad drug classes, almost always in combinations of 3-4 agents.
Drug Classes
1. Alkylating Agents (traditional chemotherapy)
| Drug | Route | Notes |
|---|---|---|
| Melphalan | IV or oral | Backbone of high-dose conditioning before stem cell transplant (200 mg/m²); oral melphalan used in elderly/frail patients |
| Cyclophosphamide | Oral or IV | Part of VCd (CyBord) regimen; used in transplant-ineligible patients and renal failure |
| Bendamustine | IV | Occasional use in relapsed disease |
2. Proteasome Inhibitors (PIs)
Block the cell's waste-disposal system, causing toxic protein buildup in myeloma cells.
| Drug | Route | Notes |
|---|---|---|
| Bortezomib (Velcade) | SC or IV | First PI approved; backbone of VRd, VCd; safe in renal failure; risk of peripheral neuropathy |
| Carfilzomib (Kyprolis) | IV | Second-generation PI; fewer neuropathy issues; more cardiotoxicity; used in KRd; phase 3 COBRA trial (2025) showed KRd superior to VRd in MRD-negative response |
| Ixazomib (Ninlaro) | Oral | Only oral PI; used in IRd; convenient for maintenance |
3. Immunomodulatory Drugs (IMiDs)
Activate T-cells and NK cells against myeloma; anti-angiogenic; anti-inflammatory.
| Drug | Route | Notes |
|---|---|---|
| Thalidomide | Oral | Oldest IMiD; teratogenic; risk of DVT and neuropathy; less used now |
| Lenalidomide (Revlimid) | Oral | Workhorse of myeloma therapy; part of VRd, DRd, KRd; standard maintenance post-transplant (10 mg/day); requires DVT prophylaxis |
| Pomalidomide (Pomalyst) | Oral | Most potent IMiD; used in lenalidomide-refractory relapsed disease |
4. Monoclonal Antibodies
Target specific proteins on the surface of myeloma plasma cells.
| Drug | Target | Route | Use |
|---|---|---|---|
| Daratumumab (Darzalex) | CD38 | IV or SC | Game-changing agent; now part of first-line quadruplet therapy (DVRd, DRd); FDA approved for high-risk smoldering myeloma (2025) |
| Isatuximab (Sarclisa) | CD38 | IV | Alternative to daratumumab; part of Isa-VRd (EHA-EMN 2026 guideline-recommended) |
| Elotuzumab (Empliciti) | SLAMF7 | IV | Used in relapsed disease (ERd) |
| Belantamab mafodotin (Blenrep) | BCMA | IV | ADC (antibody-drug conjugate); FDA approved 2025 in combination with bortezomib + dexamethasone for relapsed/refractory disease |
5. Corticosteroids
Essential partner drugs in nearly every myeloma regimen.
| Drug | Dose | Role |
|---|---|---|
| Dexamethasone | 20-40 mg weekly | Direct anti-myeloma activity; enhances efficacy of partners; reduces infusion reactions |
| Prednisone | Variable | Used in MP (melphalan-prednisone) in older regimens |
6. Newer Targeted Agents
| Drug | Class | Target | Use |
|---|---|---|---|
| Venetoclax | BCL-2 inhibitor | BCL-2 | Active specifically in t(11;14) myeloma only; NOT recommended in other subtypes (worse OS) |
| Selinexor (Xpovio) | Exportin-1 inhibitor | XPO1 | Oral; used in triple-class refractory disease; 2025 SCOPE trial: SPd regimen active in relapsed/refractory |
| Ide-cel / Cilta-cel | CAR-T cell therapy | BCMA | See section below |
| Teclistamab, Elranatamab, Talquetamab | Bispecific antibodies | BCMA / GPRC5D | Off-the-shelf T-cell engagers; active in heavily pre-treated disease |
Treatment by Disease Stage
Newly Diagnosed - Transplant Eligible
Per current ASCO/Ontario Health 2025 Living Guideline and EHA-EMN 2026 recommendations:
Quadruplet induction (preferred): Dara-VRd (Daratumumab + Bortezomib + Lenalidomide + Dexamethasone) or Isa-VRd → Stem cell collection → Autologous SCT (melphalan 200 mg/m² conditioning) → Lenalidomide maintenance (standard risk) or Bortezomib + Lenalidomide (high risk)
Triplet VRd alone remains acceptable in standard-risk patients per Rajkumar 2024 (Am J Hematol, PMID 38943315).
Newly Diagnosed - Transplant Ineligible / Frail
- DRd (Daratumumab + Lenalidomide + Dexamethasone) until progression, OR
- VRd for 9-12 cycles then lenalidomide maintenance
- VCd (Bortezomib + Cyclophosphamide + Dexamethasone) - alternative in severe renal failure or if lenalidomide unavailable
Relapsed / Refractory Disease
The principle: use a triplet containing drugs different from what the patient has already received. Options include:
- KRd (Carfilzomib + Lenalidomide + Dexamethasone)
- DPd (Daratumumab + Pomalidomide + Dexamethasone)
- VDT-PACE (intensive salvage regimen for aggressive/plasma cell leukaemia)
- CAR-T: Ide-cel or Cilta-cel (targeting BCMA) - for patients who have had 2+ prior lines
- Bispecific antibodies: Teclistamab, elranatamab (BCMA); talquetamab (GPRC5D) - ready-to-use, no manufacturing wait
- If relapse >6 months after stopping therapy: reintroduction of the original regimen is reasonable
Key Side Effects to Monitor
| Drug/Class | Key Toxicities |
|---|---|
| Bortezomib | Peripheral neuropathy, thrombocytopenia |
| Carfilzomib | Cardiac toxicity, hypertension, dyspnoea |
| Lenalidomide/Thalidomide | DVT/PE (requires prophylaxis), fatigue, cytopenias |
| Daratumumab | Infusion reactions (first dose), immunosuppression |
| Melphalan (high dose) | Mucositis, myelosuppression, infection |
| CAR-T / Bispecifics | Cytokine release syndrome, neurotoxicity (ICANS) |
| Dexamethasone | Hyperglycaemia, insomnia, fluid retention, infection |
The Trend: Moving Toward Quadruplets
The field has shifted from doublets (Rd) → triplets (VRd) → quadruplets (Dara-VRd/Isa-VRd). Each step has improved depth of response and survival. Long-term survival (10+ years after a single line of treatment) is now increasingly reported, per the International Myeloma Foundation (Oct-Nov 2025).
This is a shared conversation. Sign in to Orris to start your own chat.